SG1906 for CLDN18.2-Positive Solid Tumors

NCT05857332 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Unresectable or Metastatic Solid Tumors

Interventions

DRUG: SG1906

Sponsor

Hangzhou Sumgen Biotech Co., Ltd.